ABSTRACT
Intermittent endocrine treatment or cyclic therapy of prostate cancer aims at prolonging survival by delaying progression to androgen independence and at improving quality of life by avoiding the side effects of continuous androgen ablation. Intermittent endocrine treatment is capable of inducing multiple apoptoic regressions and of improvement in quality of life including sexual functions. The recommended length of therapeutic period is 6-9 months. The mean off-therapy interval approaches 50% of the duration of the treatment cycle. The mean time to disease progression is 32 month. The definitive answer to the question of prolonged survival awaits the completion of ongoing randomized studies.
Subject(s)
Androgen Antagonists/administration & dosage , Antineoplastic Agents, Hormonal/administration & dosage , Prostatic Neoplasms/drug therapy , Drug Administration Schedule , Humans , MaleABSTRACT
Review of the treatment of localized prostate cancer. The major attention is devoted to the surgical treatment. The radical retropubic prostatectomy is used most frequently. Problems of the indication, anatomical foundations and the technique of the surgery are discussed. The radical perineal prostatectomy is used less frequently. The radiation therapy is an alternative to the surgical treatment. The radiation therapy is recommended by urologists in patients, for whom is this treatment considered as more advantageous.
Subject(s)
Prostatic Neoplasms/surgery , Combined Modality Therapy , Humans , Male , Prostatectomy , Prostatic Neoplasms/radiotherapyABSTRACT
The prostate grows and functions within a multihormonal environment. It consists of androgens, oestrogens, gonadotrophins, gonadotrophin-releasing hormones and gestagens. Growth factors are produced under the influence of androgen stimulation. We show all possibilities of androgen deprivation of advanced and metastatic prostate cancer.
Subject(s)
Antineoplastic Agents, Hormonal/therapeutic use , Carcinoma/therapy , Orchiectomy , Prostatic Neoplasms/therapy , Androgen Antagonists/therapeutic use , Androgens/physiology , Carcinoma/physiopathology , Humans , Male , Prostatic Neoplasms/physiopathologyABSTRACT
The authors treated 16 patients with advanced prostate carcinoma after previous orchiectomy and further progression of the disease: 9 patients with Cyclophosphamide + Ftorafur + placebo and seven patients with Cyclophosphamide + Ftorafur + Orimeten. They achieved in particular improvement of the subjective complaints, while in both groups there was objective progression of the disease. In the group with Orimeten the objective progression of the disease was slower than in the group where cytostatics alone were administered.
Subject(s)
Aminoglutethimide/therapeutic use , Carcinoma/drug therapy , Prostatic Neoplasms/drug therapy , Aged , Aged, 80 and over , Aminoglutethimide/administration & dosage , Antineoplastic Agents/therapeutic use , Carcinoma/pathology , Cyclophosphamide/administration & dosage , Drug Therapy, Combination , Humans , Male , Middle Aged , Prostatic Neoplasms/pathology , Tegafur/administration & dosageSubject(s)
Aminoglutethimide/administration & dosage , Carcinoma/drug therapy , Prostatic Neoplasms/drug therapy , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma/pathology , Drug Therapy, Combination , Humans , Male , Middle Aged , Prostatic Neoplasms/pathologySubject(s)
Amylases/blood , Isoenzymes/blood , Prostatic Neoplasms/enzymology , Humans , Male , Prostatic Hyperplasia/enzymologyABSTRACT
Serum and urinary amylase isoenzyme activities were evaluated in 70 patients with carcinoma of the prostate. The results were compared with amylase isoenzyme activities fo 20 healthy man and 30 patients with benign prostatic hypertrophy. Increased serum S-type amylase activity was found in 13 patients (18%) with carcinoma of the prostate, whereas no changes of this isoenzyme was found in benign prostatic hypertrophy. No significant changes of serum P-type amylase activities were observed in our patients.
